anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1450030 Reverse osmosis J.G GOW and A G ENGLAND 10 Sept 1973. [8 June 1972] 26679/72 Heading B1X A process for the production of an aqueous solution ofa desired concentration for medical purposes comprises passing water through a reverse osmosis column capable of retaining 100 per cent of pyrogenic materials and subsequently, in either order, passing the water through a steriliser capable of eliminating 100 per cent of bacterial material and admixing in suitable ratio the water with a desired material or with a solution of such material of higher concentration than desired. The osmotic membrane may be in the form of sprially wound tubes of cellulose acetate. The water may be filtered through glass fibre before the reverse osmosis. The steriliser may be a heat steriliser or a further filter. The product may be autoclaved before storage. Solutions of glucose or glycine may be so prepared.
1489839 Chenodeoxycholic acid INTELLECTUAL PROPERTY DEVELOPMENT CORP 7 May 1975 [7 May 1974] 19262/75 Heading C2U Chenodeoxycholic acid is treated to remove entrapped organic solvent of crystallization, e.g. by (i) dissolution in aqueous alkali and precipitation with acid; or (ii) dissolution in an alcohol and evaporation to dryness; or (iii) drying under vacuum at elevated temperature (e.g. 85-100‹ C./2 mm. Hg). The product has a m.p. of 142-145‹ C. The initial chenodeoxycholic acid is isolated from bile, purified and converted to solvates with ethyl acetate, hexane, heptane and C 5-7  cycloalkanes as described in Specifications 1,450,939 and 1,489,840. Oral compositions for dissolution of cholesterol gallstones comprise chenodeoxycholic acid treated as above and a carrier.
The present invention is one kind of human tumor M2-type pyruvate kinase antigen determinant polypeptide and antibody and their application in diagnostic kit. The human tumor M2-type pyruvate kinase antigen determinant polypeptide has one of two polypeptide segments as shown in SEQ ID No. 1 and SEQ ID No. 2 in the sequence list. The human tumor M2-type pyruvate kinase antibody is prepared with the human tumor M2-type pyruvate kinase antigen determinant polypeptide of the present inventor. The human tumor M2-type pyruvate kinase antibody may be used in preparing extracorporeal diagnosis kit for human tumor M2-type pyruvate kinase.
Subjects with a histological diagnosis of malignancy of the base of skull necessitating irradiation to a minimum of 60 Gy, ECOG PS 0-1 with no evidence of metastatic disease and an estimate life expectancy of at least 1 year and who is able to provide informed consent. Subjects will undergo standard CT simulation and radiotherapy treatment planning.
FIELD: oncology; pulmonology. SUBSTANCE: lymph incubated with chemopreparations is administered to patient intravenously so that, instead of autolymph, donor lymph belonging to the same group is used. Method is used for treatment of non-fine-cellular pulmonary cancer with chemotherapeutical preparations in situations when patients deprived of lymph intake because of cancer metastases into lymph nodes in zone of thoracic lymphatic duct or because of its obstruction due to anatomic peculiarities, i.e. when thoracic duct is in the form of plurality of branches, are treated by administration of donor lymph belonging to the same group. EFFECT: higher efficiency; prolonged duration of recidiveless period; prolonged life time for patients. 1 tbl
OBJECTIVE: The prognostic significance of isolated tumor cells (≤0.2 mm) in sentinel lymph nodes (SLNs) of endometrial cancer patients is still unclear. Our aim was to assess the prognostic value of isolated tumor cells in patients with low risk endometrial cancer who underwent SLN biopsy and did not receive adjuvant therapy. Outcomes were compared with node negative patients.
METHODS: Patients with SLNs-isolated tumor cells between 2013 and 2019 were identified from 15 centers worldwide, while SLN negative patients were identified from Mayo Clinic, Rochester, between 2013 and 2018. Only low risk patients (stage IA, endometrioid histology, grade 1 or 2) who did not receive any adjuvant therapy were included. Primary outcomes were recurrence free, non-vaginal recurrence free, and overall survival, evaluated with Kaplan-Meier methods.
RESULTS: 494 patients (42 isolated tumor cells and 452 node negative) were included. There were 21 (4.3%) recurrences (5 SLNs-isolated tumor cells, 16 node negative); recurrence was vaginal in six patients (1 isolated tumor cells, 5 node negative), and non-vaginal in 15 (4 isolated tumor cells, 11 node negative). Median follow-up among those without recurrence was 2.3 years (interquartile range (IQR) 1.1-3.0) and 2.6 years (IQR 0.6-4.2) in the SLN-isolated tumor cell and node negative patients, respectively. The presence of SLNs-isolated tumor cells, lymphovascular space invasion, and International Federation of Obstetrics and Gynecology (FIGO) grade 2 were significant risk factors for recurrence on univariate analysis. SLN-isolated tumor cell patients had worse recurrence free survival (p<0.01) and non-vaginal recurrence free survival (p<0.01) compared with node negative patients. Similar results were observed in the subgroup of patients without lymphovascular space invasion (n=480). There was no difference in overall survival between the two cohorts in the full sample and the subset excluding patients with lymphovascular space invasion.
CONCLUSIONS: Patients with SLNs-isolated tumor cells and low risk profile, without adjuvant therapy, had a significantly worse recurrence free survival compared with node negative patients with similar risk factors, after adjusting for grade and excluding patients with lymphovascular space invasion. However, the presence of SLNs-isolated tumor cells was not associated with worse overall survival.
PURPOSE:To obtain the endoplasmic reticulum having no internal oxyalkylene chain and with the number of the oxyalkylene chains increased and to maintain the activity of the inclusion by linking a specified oxyalkylene chain only to the outer surface of the reticulum by the urethane coupling to the amino group on the outer surface of the reticulum. CONSTITUTION:An oxyalkylene chain shown by formula I is linked only to the outer surface of an endoplasmic reticulum by the urethane coupling to an amino group on the outer surface of the reticulum, and the reticulum has a structure expressed by formula II. In the formulas, Y is hydrogen atom or a 1-4C alkyl, AO is a 2-4C oxyalkylene group, and (n) is the average number of mols of the alkylene group added and is an integer of 1 to 1000. The oxyalkylene groups can be the same or mutually different when n>=2 and capable of being added at random or in blocks. The Lip-NH- shows an endoplasmic reticulum contg. a phospholipid having an amino group as the reticulum forming component.
The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date. They will also receive smoking cessation behavioral counseling.
<P>PROBLEM TO BE SOLVED: To provide hydrogel particles having a good use feeling.  <P>SOLUTION: The hydrogel particles are equipped with a non-crosslinked type hydrogel continuous phase and dispersed phases dispersing in the continuous phase. Each of the dispersed phases contains solid fat and liquid oil as oily components, and also dispersing titanium oxide particles at its inside. The solid fat in the oily components contains a higher alcohol and solid paraffin, and also has 1 to 12 mass% content in the dispersed phases. The volume-based mean particle diameter of the hydrogel particles is 10 to 300 μm.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The universe of this research, which has a randomized controlled design, is all people with disabilities aged 18 and older who are attended at the Etimesgut Family and Life Center in Ankara. The inclusion criteria of this study were to be 18 years of age or older, to have a score of 17 and below according to the Lawton-Brody Instrumental Activity of Daily Living Scale, to have a score of 24 and above in the Modified Mini-Mental test. In addition, there are some exclusion criteria for research. Exclusion criteria from the study were: Having a communication problem that prevented the participant from completing the assessment and the kits; not participating regularly in the intervention program. For this study, people who attended the Family and Life Center and people with disabilities who regularly come to this center for various reasons were contacted. People (n=35) who met the criteria of the study were informed about the study and invited to participate in this study.
Dilute epinephrine in 5 percent dextrose solution or 5 percent dextrose and sodium chloride solution. These dextrose containing fluids provide protection against significant loss of potency by oxidation. Administration in saline solution alone is not recommended. Whole blood or plasma, if indicated to increase blood volume, should be administered separately.

Add 1 mL (1 mg) of epinephrine from its vial to 1,000 mL of a 5 percent dextrose containing solution. Each mL of this dilution contains 1 mcg of epinephrine.

Correct blood volume depletion as fully as possible before any vasopressor is administered. When, as an emergency measure, intraaortic pressures must be maintained to prevent cerebral or coronary artery ischemia, epinephrine can be administered before and concurrently with blood volume replacement.

Whenever possible, give infusions of epinephrine into a large vein. Avoid using a catheter tie-in technique, because the obstruction to blood flow around the tubing may cause stasis and increased local concentration of the drug. Occlusive vascular diseases (for example, atherosclerosis, arteriosclerosis, diabetic endarteritis, Buerger’s disease) are more likely to occur in the lower than in the upper extremity; therefore, avoid the veins of the leg in elderly patients or in those suffering from such disorders. There is potential for gangrene in a lower extremity when infusions of catecholamine are given in an ankle vein.

To provide hemodynamic support in septic shock associated hypotension in adult patients, the suggested dosing infusion rate of intravenously administered epinephrine is 0.05 mcg/kg/min to 2 mcg/kg/min, and is titrated to achieve a desired mean arterial pressure (MAP). The dosage may be adjusted periodically, such as every 10 - 15 minutes, in increments of 0.05 mcg/kg/min to 0.2 mcg/kg/min, to achieve the desired blood pressure goal.

Continuous epinephrine infusion is generally required over several hours or days until the patient’s hemodynamic status improves. The duration of perfusion or total cumulative dose cannot be predicted.

After hemodynamic stabilization, wean incrementally over time, such as by decreasing doses of epinephrine every 30 minutes over a 12- to 24-hour period.
The invention discloses a graphical human thermal stress evaluation method based on subjective feeling, which comprises the following steps: step 1: constructing a human body thermal stress evaluation partition map, wherein the abscissa is the fatigue degree score RPE, and the ordinate is the thermal sensation score RTS. The three thermal stress partition boundaries are divided into four areas with low to high thermal stress levels. The boundary line determination method comprises the following steps: (a) And fitting a functional relation between the perceived thermal stress index PeSI and the physiological thermal stress index PSI by adopting regression analysis to obtain three partition limit values. (b) And substituting the three demarcation values into the PeSI calculation formula to obtain three linear function relation formulas. (c) Three primary function line segments are made in the graph to form three thermal stress partition boundaries; step 2: the worker selects the fatigue degree score RPE and the thermal sensation score RTS, and then determines the thermal stress level zone to which the coordinate point thereof belongs in the evaluation zone map, thereby determining the thermal stress level. The method can accurately evaluate the thermal stress of the human body and avoid the occurrence of heat injury.
Therapeutic complexes comprising plural therapeutic compounds self assembled into high axial ratio microstructures are described. The therapeutic complexes satisfy the formula HARM-Th, wherein HARM is a high axial ratio forming material and Th is a therapeutic coupled to or associated with the HARM. The therapeutic complexes also can satisfy the formula HARM- S- Th, wherein S is a spacer. Release of the therapeutic by the complex generally follows either 0-order kinetics or pseudo-first order kinetics. A method for delivering therapeutics to organisms, particularly humans, also is described. The method comprises administering an effective amount of (1) a ligand, such as a therapeutic, self-assembled into a HAR microstructure, or (2) a ligand, such as a therapeutic, coupled to or associated with a material capable of thereafter self-assembling into a high axial ratio microstructure, to the mammal. Nucleic acids are an example of a ligand that can be administered effectively according to this method through noncovalent attachment to the HARM-forming materials.
The persisting risk of long-term health consequences of SARS-CoV-2 infection and the protection against such risk conferred by COVID-19 vaccination remains unclear. Here we conducted a retrospective territory-wide cohort study on 1,175,277 patients with SARS-CoV-2 infection stratified by their vaccination status and non-infected controls to evaluate the risk of clinical sequelae, cardiovascular and all-cause mortality using a territory-wide public healthcare database with population-based vaccination records in Hong Kong. A progressive reduction in risk of all-cause mortality was observed over one year between patients with SARS-CoV-2 infection and controls. Patients with complete vaccination or have received booster dose incurred a lower risk of health consequences including major cardiovascular diseases, and all-cause mortality than unvaccinated or patients with incomplete vaccination 30-90 days after infection. Completely vaccinated and patients with booster dose of vaccines did not incur significant higher risk of health consequences from 271 and 91 days of infection onwards, respectively, whilst un-vaccinated and incompletely vaccinated patients continued to incur a greater risk of clinical sequelae for up to a year following SARS-CoV-2 infection. This study provided real-world evidence supporting the effectiveness of COVID-19 vaccines in reducing the risk of long-term health consequences of SARS-CoV-2 infection and its persistence following infection.
This is a randomized, double-blind, placebo-controlled, clinical trial assessing the efficacy of Ultravate ointment in combination with Lac-Hydrin lotion in the treatment of plaque psoriasis. In the first phase, patients will be treated for two weeks with combination therapy using Ultravate ointment twice daily along with Lac-Hydrin lotion twice daily. After two weeks, psoriasis plaques will be evaluated to test treatment efficacy. Those patients with a significant clinical improvement per investigator clinical assessments, will be randomized in a 1:1 fashion into a maintenance phase and receive Lac-Hydrin lotion twice daily everyday with placebo ointment or Ultravate ointment twice daily on weekends only. Continuous use of Ultravate ointment will be discontinued following two weeks of treatment in compliance with its FDA indication. Patients will be evaluated every 4 weeks (monthly) through the maintenance phase. The purpose of this second phase of the study is to investigate whether use of Ultravate on weekends only can minimize risk of plaque recurrence, maximize duration of therapeutic effect, while limiting the need for the use of long-term continuous topical corticosteroid treatment. As well, the second phase of the study is to investigate whether twice daily Lac-Hydrin lotion has an impact in maximizing the duration of therapeutic effect as well as minimizing local cutaneous side effects such as skin atrophy and telangiectasia. Part of this clinical study consists of the use of patient and self-assessment questionnaires and the use of non-identifying digital photography of target lesions. The hypothesis is that Ultravate ointment on weekends only will be statistically more efficacious at maintaining an excellent initial clinical response and its combination with Lac-Hydrin lotion will help to minimize any local cutaneous side effects as well as enhance its therapeutic effect.
Recent empirical research posits a link between lymphocyte subgroups and both the incidence and prognosis of sepsis. Nevertheless, the potential influence of multiple confounding variables obscures any clear causative correlation. Utilizing a 2-sample Mendelian randomization approach, we conducted a meta-analysis of lymphocyte subgroups. In a genome-wide association study, flow cytometry was applied to a lymphocyte subgroup comprising 3757 Sardinians to identify genes influenced by blood immune cells. The sepsis meta-analysis data were sourced from the UK Biobank database, including 11,643 treatment groups and 47,841 control groups. Inverse variance-weighted, Mendelian randomization-Egger regression, weighted median, simple mode, and weighted mode methods were deployed to ascertain the causative relationship between lymphocyte subgroup and sepsis. Cochran Q test, the Mendelian randomization-Egger intercept test, and funnel plots were leveraged to assess the robustness of study findings. The inverse variance-weighted analysis disclosed that the absolute count of CD4 regulatory T cells (CD4 Treg AC) within the lymphocyte subgroup has a causative link to an elevated risk of sepsis, with an odds ratio of 1.08 and a 95% confidence interval of 1.02 to 1.15 (P = .011). Compared to individuals not subjected to this factor, those exposed to CD4 Treg AC have a marginally elevated sepsis risk by approximately 0.08%. No causative relationships were observed between sepsis risk and the absolute counts of other lymphocyte subgroups such as CD8+ T cells, CD4+ CD8dim T cells, natural killer T cells, B cells (B cell absolute count), and HLA DR+ natural killer cells. The 2-sample Mendelian randomization study indicated a causal relationship between the level of CD4 Treg AC and the increased risk of sepsis. The elevation in circulating lymphocyte subgroups suggests higher susceptibility to sepsis, affirming the immune susceptibility inherent to this condition. The findings from our study may propose potential targets for diagnosis and intervention of sepsis.
Substantial efforts are underway toward optimizing the diagnosis, monitoring, and treatment of seizures and epilepsy. We describe preclinical programs in place for screening investigational therapeutic candidates in animal models, with particular attention to identifying and eliminating drugs that might paradoxically aggravate seizure burden. After preclinical development, we discuss challenges and solutions in the design and regulatory logistics of clinical trial execution, and efforts to develop disease biomarkers and interventions that may be not only seizure-suppressing, but also disease-modifying. As disease-modifying treatments are designed, there is clear recognition that, although seizures represent one critical therapeutic target, targeting nonseizure outcomes like cognitive development or functional outcomes requires changes to traditional designs. This reflects our increasing understanding that epilepsy is a disease with profound impact on quality of life for the patient and caregivers due to both seizures themselves and other nonseizure factors. This review examines selected key challenges and future directions in epilepsy diagnostics and therapeutics, from drug discovery to translational application.
The invention is entitled "envelope wall surface defining a cavity of an organ". A method for determining an envelope surface of a cavity of an organ of a patient includes receiving a plurality of data points including respective position measurements in the cavity. A first iterative process is performed that gradually partitions a sub-volume into smaller sub-volumes until the density of the data points in each sub-volume falls below a predefined density. A second iterative process is performed that progressively discards subvolumes that are completely enclosed by the filled subvolume and discards the data points contained in the discarded subvolumes. Defining the envelope surface of the cavity based on the data points remaining after the second iterative process. Presenting the envelope surface of the cavity to a user.
A cosmetic composition for improving the skin elasticity and wrinkle is provided by improve dermis-epidermis layer by efficiently absorbing an efficient component and enhance skin elasticity. A cosmetic composition for enhancing the skin elasticity comprises 0.01-10.0% by weight of soluble film former, 1.0-40.0% by weight of polyhydric alcohol, 1.0-20.0% by weight of polar oil, and efficient component of elasticity improvement. The soluble film former is hydroxyethylacrylate/sodiumacryloyldimethyltaurate copolymer, polyvinylpyrrolidone, vinylpyrrolidone vinylacetate copolymer, polyquaternium hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose or hydroxypropyl guar. The polyhydric alcohol is glycerin, propylene glycol, dipropylene glycol, 1,3-butylene glycol, polyethylene glycol or sorbitol. The polar oil is ester oil. The efficient component of elasticity improvement is retinol, adenosine or peptide. The cosmetic composition is used in a form of emulsion of oil in water(O/W) or water in oil(W/O), lotion, cream, emulsion, patch, stick or spray.
The invention concerns the preparation and use of a live tumour-cell vaccine which contains three additional genes prepared by genetic-engineering techniques: a) a gene coding for a cell-surface protein with immunostimulatory activity, b) a cytokin gene and c) the thymidine kinase gene. The fields of application of the invention are medicine and genetic engineering. The live vaccine proposed owes its effect to the fact that a synergistic anti-tumour response is induced by the multiple transfer of genes which code for immunostimulatory activity. This leads to reliable repulsion of the vaccine cells and enables cells capable of multiplying to be injected as a vaccine. As an additional safety marker, the vaccine cells are given the thymidine kinase gene which enables the vaccine cells to be selectively killed in vivo. The combinatory expression of genes with immunostimulatory activity improves the vaccine effect in comparison with prior art tumour-cell vaccines, and a live tumour-cell vaccine is more effective than a vaccine consisting of cells which are incapable of multiplying. The vaccine is intended for use in the genetic therapy of cancer patients.
Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and they will perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
Participants are prescribed olaparib which is taken orally at home, twice daily, 300 mg in 28 day cycles, as first line therapy. For second line (crossover), carboplatin is administered AUC 5 IV every 21 days thereafter.